



# AUT INSTITUTE OF BIOMEDICAL TECHNOLOGIES

## NOVEL THERAPIES FOR TREATING INFLAMMATION AND INFECTION IN THE LUNG

**IBTec WISHES TO INVITE YOU TO ATTEND THIS PRESENTATION BY:**



### **PROFESSOR PAUL YOUNG**

**Deputy Executive Director & Head of Respiratory Technology  
Woolcock Institute**

**Professor of Respiratory Technology  
Sydney Medical School, University of Sydney**

**Date: Thursday 1 September 2016**

**Time: 12:00 noon**

**Venue: WS114, Level 1, WS Building**

Recurring inflammation and infection in the lung is a serious issue for people suffering with severe asthma, chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF). While advances have been made in treating inflammation locally (mainly via the introduction of inhaled steroids) device efficiency is still considered sub-optimum at best (<20% in some cases). In comparison, local therapies for treating infection are all but non-existent. This presentation looks at a number of novel approaches for controlling inflammation and infection in respiratory disorders. We will investigate whether it is possible to deliver high dose therapies to the lung using simple high efficiency disposable inhalers and examine whether the repurposing of drugs already in use for other diseases such as high cholesterol, may be a route to improving health care outcomes for those suffering from these chronic lung diseases.

#### **Bio**

Paul is Deputy Executive Director & Head of Respiratory Technology at the Woolcock Institute and Professor of Respiratory Technology at the Sydney Medical School, University of Sydney. Paul has made a significant contribution in the field of advanced drug delivery and inhalation science. Paul has published >180 peer reviewed international journal articles (~3500 citations), 5 patents, 13 book chapters and in excess of 100 conference proceedings. Paul has an H-index of 33 and 5-year i10 index of 100. Paul was an Australian Research Council Future Fellow and is a Chartered Chemist of the Australian Royal Society of Chemistry. He has given invited conference seminars on multiple occasions and has been on the organising committees for international science conferences. Paul has been appointed onto the Australian Research Council College, the external TGA medical advisory committee, and editorial boards of range of journals including Pharmaceutical Research, Journal of Pharmacy and Pharmacology, Drug Development and Industrial Pharmacy, AAPS PharmSciTech, and Respiratory Drug Delivery. Paul was a founding director of Nanopharm Ltd in the UK and is Director of Pulmatix Pty Ltd in Australia, a specialist contract drug development and testing company. Paul collaborates with both academia and industry on an international level and has attracted >AUD 15 million dollars in funding within the area of inhalation medicine.